Umoove

Umoove has developed face and eye tracking software designed for use on any mobile device with no additional hardware needed. Through the use of a downloaded app, users can enable any device to see them and look them in the eye. The company’s technology opens new possibilities in many markets (e.g. gaming, advertising, sports, wearable AR/VR, etc.) but particularly in the field of healthcare, where tracking a person’s eyes can provide a window into analyzing brain activity. Conditions such as ADHD, concussions, strokes, autism, and Parkinson’s disease, among others, can all be observed through the eyes. Umoove has created software to address the challenges of mobile environments, including shakiness, lighting, and limited hardware resources. The technology runs at a CPU as low as 5% in real time and needs nothing but the raw frames of the front-facing camera for input. In addition to the core technology, Umoove has developed an interpretation layer that turns face and eye movements into an interactive language capable of providing valuable data. Umoove’s technology is built on top of unique algorithms and has more than 15 patents pending.

Umoove has raised $2.75M in total funding across 4 rounds. The company is currently at the Mature stage. Key investors include Bouaziz & Partners, Flint Capital.

Umoove was founded in 2012 by Tuvia Elbaum (Co-founder, Board Member & CMO), Yitzi Kempinski (Co-founder, CEO & CTO), Nir Blushtein (Co-Founder & COO).

Umoove operates in Health Tech & Life Sciences, Digital Healthcare, Digital Medical Diagnostics, with core technologies in Simulation & Imaging, Virtual Reality, Augmented Reality, Artificial Intelligence, Computer Vision, Platforms & Interfaces, Software. Target customers: Enterprise & Professional Services, Marketing & Sales, Advertising, Healthcare & Life Sciences, Healthcare, Providers.

Umoove is based in HaMarpe Street 8, Jerusalem, Israel, Jerusalem District.